Cytosorbents Corp (CTSO)

Cytosorbents (CTSO) Stock Price & Analysis


CTSO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.03 - $4.59
Previous Close$1.19
Average Volume (3M)94.13K
Market Cap
Enterprise Value$64.34M
Total Cash (Recent Filing)$8.36M
Total Debt (Recent Filing)$18.04M
Price to Earnings (P/E)-2.2
Mar 07, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding44,438,509
10 Day Avg. Volume150,877
30 Day Avg. Volume94,126
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)2.86
Price to Sales (P/S)1.55
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.53
Enterprise Value/Gross Profit3.10
Enterprise Value/Ebitda-5.06
Price Target Upside381.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Ownership Overview

12.32% Insiders
7.89% Mutual Funds
25.68% Other Institutional Investors
54.12% Public Companies and
Individual Investors


What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $1.03 and its highest was $4.59 in the past 12 months.
    What is Cytosorbents Corp’s market cap?
    Currently, no data Available
    When is Cytosorbents Corp’s upcoming earnings report date?
    Cytosorbents Corp’s upcoming earnings report date is Mar 07, 2024 which is in 98 days.
      How were Cytosorbents Corp’s earnings last quarter?
      Cytosorbents Corp released its earnings results on Nov 09, 2023. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.123 by -$0.087.
        Is Cytosorbents Corp overvalued?
        According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cytosorbents Corp pay dividends?
          Cytosorbents Corp does not currently pay dividends.
          What is Cytosorbents Corp’s EPS estimate?
          Cytosorbents Corp’s EPS estimate is -$0.14.
            How many shares outstanding does Cytosorbents Corp have?
            Cytosorbents Corp has 44,438,510 shares outstanding.
              What happened to Cytosorbents Corp’s price movement after its last earnings report?
              Cytosorbents Corp reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.123. Following the earnings report the stock price went up 0.794%.
                Which hedge fund is a major shareholder of Cytosorbents Corp?
                Among the largest hedge funds holding Cytosorbents Corp’s share is Royce & Associates LLC. It holds Cytosorbents Corp’s shares valued at N/A.


                  Company Description

                  Cytosorbents Corp

                  CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.


                  Top 5 ETFs holding CTSO

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold CTSO. The ETFs are listed according to market value of CTSO within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Aethlon Medical
                  Bioxcel Therapeutics
                  Eagle Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis